Low dose Emodin induces tumor senescence for boosting breast cancer chemotherapy via silencing NRARP

Journal Article · Wed Nov 14 23:00:00 EST 2018 · Biochemical and Biophysical Research Communications

DOI:https://doi.org/10.1016/J.BBRC.2018.09.045· OSTI ID:23134103

Zu, Cong; Qin, Guangyuan; Yang, Chunshu; Liu, Ning; He, Anning ^[1]; Zhang, Mingdi ^[2]; Zheng, Xinyu ^[1]

---

1. Lab 1, Cancer Institute of the First Affiliated Hospital, China Medical University, Shenyang, Liaoning, 110001 (China)
2. Department of Breast Surgery, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, 200011 (China)

Highlights: • The chemoresistance often limits clinical effectiveness of chemotherapy on breast cancer treatment. • Emodin potentiates 5-FU-induced apoptosis of breast cancer cells. • Low dose Emodin induces cellular senescence in breast cancer cells by inhibition of Nrarp. The resistance to 5-FU often limits its clinical effectiveness on breast cancer treatment. Combination therapy thus is employed to overcome this treatment resistance. We here report a potent antitumor effect of Emodin at low dose on chemotherapy sensitivity of MCF-7 breast cancer cells.

• OSTI ID: 23134103
• Journal Information: Biochemical and Biophysical Research Communications, Journal Name: Biochemical and Biophysical Research Communications Journal Issue: 4 Vol. 505; ISSN 0006-291X; ISSN BBRCA9
• Country of Publication: United States
• Language: English

Related Subjects

60 APPLIED LIFE SCIENCES
APOPTOSIS
CHEMOTHERAPY
MAMMARY GLANDS
NEOPLASMS